NASDAQ · LBRX
LB Pharmaceuticals Inc
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for LBRX: Nov 5, 2026
LB Pharmaceuticals Inc Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.61. The reported EPS for the same quarter last year was $-0.61.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.61 | $-1.52 | $-1.72 | 4 |
| Dec 2026 | $-1.64 | $-1.49 | $-1.86 | 4 |
| Mar 2027 | $-1.57 | $-1.55 | $-1.59 | 3 |
| Jun 2027 | $-1.49 | $-1.34 | $-1.59 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · Fintel · RTTNews · BNK Invest- MarketBeat · Oct 27, 9:04 PM EDTLB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in SchizophreniaLB Pharmaceuticals (NASDAQ:LBRX) outlined its clinical and commercial plans for LB-102, an investigational antipsychotic designed as a structural modification of amisulpride, during its first R&D Day in New York. The company said it expects three clinical readouts over the next t
- Fintel · Oct 6, 9:37 AM EDTGuggenheim Initiates Coverage of LB Pharmaceuticals at BuyFintel reports that on October 6, 2026, Guggenheim initiated coverage of LB Pharmaceuticals (NASDAQGM:LBRX) with a Buy recommendation. This coverage initiation follows other recent analyst actions for LB Pharmaceuticals. On October 5, 2026, Roth Capital downgraded the company fro
- RTTNews · Sep 15, 8:53 AM EDTLB Pharmaceuticals Appoints Susan Kozauer As CMO(RTTNews) – LB Pharmaceuticals Inc. (LBRX), a neuromedicines company, on Tuesday appointed Susan Kozauer as Chief Medical Officer.
- RTTNews · Sep 3, 9:22 AM EDTLB Pharmaceuticals Names Joseph Miller CFO(RTTNews) – On Thursday, LB Pharmaceuticals Inc. (LBRX) announced the appointment of Joseph Miller as Chief Financial Officer. LB Pharma is a neuromedicines company dedicated to developing and commercializing therapies that address the multiple dimensions of underserved brain dis
- BNK Invest · Aug 19, 10:36 AM EDTLBRX Crosses Above Average Analyst TargetIn recent trading, shares of LB Pharmaceuticals Inc (Symbol: LBRX) have crossed above the average analyst 12-month target price of $48.11, changing hands for $48.77/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade
- RTTNews · Aug 11, 1:55 PM EDTLB Pharmaceuticals Accelerates LB-102 Schizophrenia Program; Phase 3 Data Expected In 1H27(RTTNews) – LB Pharmaceuticals (LBRX), a neuromedicines company developing therapies for underserved brain disorders, recently reported its second-quarter 2026 financial results and provided a corporate update, with investors focusing on the accelerated development of LB-102 and
- RTTNews · Jul 29, 11:40 PM EDTTop Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up(RTTNews) – Today's top biotech gainers include SciSparc, after its subsidiary successfully completed internal validation of a proprietary quantum sampling platform designed to analyze clinical trial data; Avantor, following the release of its second-quarter financial results and
- RTTNews · Jul 29, 4:21 AM EDTBiotech Stocks At 52-Week Highs – INCY Rises With Q2 Results, PLSE, SI, BVS, LBRX(RTTNews) – The following biotech stocks reached a 52-week high on July 28, 2026, driven by key catalysts including positive quarterly results.
- RTTNews · Jul 23, 4:36 AM EDTBiotech Stocks At 52-Week Highs – ADVB Surges +73%, BLFS Rises After Acquisition, FBRX, SLN, LBRX(RTTNews) – The following biotech stocks reached a 52-week high on July 22, 2026, driven by key catalysts including prospective clinical trial results and announced acquisitions.
- RTTNews · Jul 22, 11:09 PM EDTTop Biotech Gainers: ZCMD Surges 190%, LABT Advances On Nu-3 Progress, ARWR Hits The Targets(RTTNews) – Today's top gainers in the healthcare sector include Zhongchao, surging more than 190%; Lakewood-Amedex, advancing on positive antimicrobial drug progress; Arrowhead, delivering encouraging severe hypertriglyceridemia trial results; and LB Pharma, accelerating the LB-
- RTTNews · Jul 22, 12:10 PM EDTLB Pharma Accelerates Phase 3 Timeline For LB-102 In Phase 3 Schizophrenia Trial(RTTNews) – LB Pharmaceuticals Inc (LBRX), a clinical-stage biopharmaceutical company, said Tuesday it expects to report topline results from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027, ahead of its previous guidance of the second half o
- Zacks · May 26, 12:00 PM EDTAll You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to BuyLB Pharmaceuticals Inc (LBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for LB Pharmaceuticals Inc from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.